Vaccinex announces publication on the generation, characterization and preclinical evaluation of its lead clinical-stage antibody VX15/2503

ROCHESTER, N.Y., October 6, 2015 – Vaccinex Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, today announced publication of a manuscript entitled “Generation and preclinical characterization of an antibody specific for SEMA4D.” in the journal MAbs (2015 Oct 2:0).  The new publication describes the generation and characterization of VX15/2503, an anti-Semaphorin 4D antibody currently in human clinical trials, including in vitro functional testing, epitope mapping, and in vivo demonstration of efficacy in an animal model of rheumatoid arthritis.

 

About Vaccinex, Inc.

Vaccinex, Inc. is a privately held clinical-stage immunotherapy company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, including Huntington’s disease. Vaccinex utilizes its proprietary ActivMAb® Antibody Discovery Technology for rapid, mammalian cell-based antibody selection to build its antibody pipeline and in service to its biopharmaceutical partners. ActivMAb® combines the advantages of rapid and sensitive selection by virus panning and cell sorting in one technology, with intrinsic selection of antibodies that are efficiently expressed and stable in mammalian cells, which we believe is different than other selection technologies. Vaccinex is based in Rochester, New York. For more information and to contact Vaccinex, visit www.vaccinex.com.

CONTACT: Vaccinex    info@vaccinex.com

 

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements reflecting the current beliefs and expectations of management. Words such as “may,” “believe,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions, as well as other words or expressions referencing future events, conditions or circumstances, are intended to identify forward-looking statements. Forward-looking statements contained in this press release include statements about the initiation of a Phase 2 clinical trial for the Company’s lead monoclonal antibody, VX15/2503.  Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including as a result of the inherent challenges in clinical development. All forward-looking statements are based on Vaccinex’s expectations and assumptions as of the date of this press release, and actual results may differ materially. Except as required by law, Vaccinex expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.